Ludwigshafen, Germany

Ben Klünder

This inventor holds 36 USPTO granted patents and 15 published patent applications, primarily in Pharmaceutical Chemistry. Top assignee: Abbvie Inc.. Active years: 2019-2026.

USPTO Granted Patents = 36 

% Patents Active = 100.0

Average Co-Inventor Count = 6.4

ph-index = 18

Forward Citations = 554(Granted Patents)


Company Filing History:


Years Active: 2019-2026

Loading Chart...
Areas of Expertise:
Drug Formulation
Crohn's Disease
Ulcerative Colitis
Pyrrolidine
Imidazo
Pyrazin
Trifluoroethyl
Solid State Forms
Chemical Processes
Carboxamide
36 patents (USPTO):Explore Patents

Title: The Innovative Journey of Ben Klünder

Introduction: Ben Klünder, a visionary inventor hailing from Ludwigshafen, Germany, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Ben Klünder's latest patents include cutting-edge technologies in the renewable energy sector, specifically focusing on solar power optimization and energy storage solutions.

Career Highlights: Throughout his illustrious career, Ben Klünder has been at the forefront of innovation, with a strong emphasis on sustainability and environmental impact. His inventions have revolutionized the way we harness and utilize energy, earning him recognition as a pioneer in the industry.

Collaborations: Ben Klünder has collaborated with leading research institutions and universities to further develop his inventions and bring them to market. His partnerships with top companies in the energy sector have led to the successful implementation of his technologies on a global scale.

Conclusion: In conclusion, Ben Klünder's passion for innovation and dedication to creating a more sustainable future have solidified his position as a trailblazer in the world of technology. His inventive spirit continues to inspire the next generation of inventors and shape the landscape of renewable energy solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…